NanoRepro AG (FRA:NN6)

Market Cap	20.50M
Revenue (ttm)	3.56M
Net Income (ttm)	-3.20M
Shares Out	n/a
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,602
Average Volume	12,460
Open	1.695
Previous Close	1.630
Day's Range	1.625 - 1.695
52-Week Range	1.165 - 2.250
Beta	n/a
RSI	55.54
Earnings Date	Jun 5, 2025

About NanoRepro AG

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and mi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 18
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NN6

Financial Performance

In 2023, NanoRepro AG's revenue was 3.18 million, a decrease of -91.79% compared to the previous year's 38.79 million. Losses were -4.69 million, 25.8% more than in 2022.